Enhertu delays disease progression in certain patients with metastatic breast cancer
Compared with standard-of-care chemotherapy, trastuzumab deruxtecan demonstrated a statistically significant improvement in PFS among certain patients with metastatic breast cancer, according to a press release from the manufacturer.
Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a HER2-directed antibody-drug conjugate consisting of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads.
Compared with standard-of-care chemotherapy, trastuzumab deruxtecan demonstrated a statistically significant improvement in PFS among certain patients with metastatic breast cancer. Researchers conducted the randomized phase 3 DESTINY-Breast06 trial to assess the efficacy and safety of Enhertu vs. investigator’s choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) among patients with hormone receptor-positive, HER2-low or HER2-ultralow advanced or metastatic breast cancer who received a previous line of endocrine-based therapy
Among 866 study participants, 713 had HER2-low and 153 had HER2-ultralow breast cancer; PFS in the hormone receptor-positive and HER2-low patient population served as the study’s primary efficacy endpoint, with key secondary endpoints including OS in patients with HER2-low expression and PFS by blinded independent central review and OS in the overall trial population.
Study investigators reported an improvement in PFS among the primary trial population of participants with HR-positive, HER2-low metastatic breast cancer who received trastuzumab deruxtecan compared with standard-of-care chemotherapy, as well as a statistically significant and clinically meaningful improvement in PFS among the overall trial population, which appeared to be consistent among patients with both HER2-low and HER2-ultralow expression.
“DESTINY-Breast06 shows that Enhertu could become a new standard of care for patients with HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy,” Susan Galbraith, MBBChir, PhD, MRCP, FRCR, FMedSci, executive vice president of oncology research and development for AstraZeneca, said in a press release. “These data underscore the potential for treatment with Enhertu across the spectrum of hormone-receptor-positive breast cancer, further redefining the treatment of metastatic breast cancer.”
The safety profile for trastuzumab deruxtecan observed by researchers remained consistent with previous breast cancer clinical trials. Complete results will be presented at an upcoming medical meeting, according to the release.
May 1, 2024
